5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate
Abstract
:1. Introduction
2. Results
3. Materials and Methods
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Mok, S.; Koya, R.C.; Tsui, C.; Xu, J.; Robert, L.; Wu, L.; Graeber, T.G.; West, B.L.; Bollag, G.; Ribas, A. Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Res. 2014, 74, 153–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tap, W.D.; Wainberg, Z.A.; Anthony, S.P.; Ibrahim, P.N.; Zhang, C.; Healey, J.H.; Chmielowski, B.; Staddon, A.P.; Cohn, A.L.; Shapiro, G.I.; et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 2015, 373, 428–437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lamb, Y.N. Pexidartinib: First Approval. Drugs 2019, 79, 1805–1812. [Google Scholar] [CrossRef] [PubMed]
- Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol. Res. 2020, 152, 104609. [Google Scholar] [CrossRef] [PubMed]
- Ibrahim, P.N.; Visor, G.C. Solid Forms of a Compound Modulating Kinases. International Patent WO2016179415, 10 November 2016. [Google Scholar]
- Chen, M.; Zhang, Y.; Zou, P.; Zhang, X. Preparation of PLX3397 Hydrochloride Crystal Forms. International Patent WO2017215521, 21 December 2017. [Google Scholar]
- Li, H.; Li, Y.; Huang, X. Green Preparation of Pexidartinib as Tyrosine Kinase Inhibitor. China Patent CN113444083, 28 September 2021. [Google Scholar]
- Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. Acta Crystallogr. A 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Crystallogr. C 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Compound | (II)·2H2O |
---|---|
Moiety formula | (C20H17ClF3N5)2+ · 2Cl− · 2H2O |
Empirical formula | C20H21Cl3F3N5O2 |
Formula weight | 526.77 |
Temperature (K) | 183(2) |
Wavelength (Å) | 0.71073 |
Crystal system | Monoclinic |
Space group | P21/c |
a (Å) | 5.4641(3) |
b (Å) | 16.2163(10) |
c (Å) | 26.3877(17) |
β (°) | 93.0718(18) |
Unit cell volume (Å3) | 2334.8(2) |
Z/Z’ | 4/1 |
Reflections collected/Rint | 34,479/0.0479 |
Data/restraints/parameters | 4145/8/331 |
Goodness-of-fit on F2 | 1.044 |
R1 [I > 2 σ(I)] | 0.0365 |
wR2 (all data) | 0.0879 |
Largest diff. peak and hole (e · Å−3) | 0.444 and −0.368 |
CCDC no. | 2265163 |
D—H···A | dD—H | dH···A | dD···A | <(DHA) |
---|---|---|---|---|
N1—H1N···Cl2 | 0.878(16) | 2.242(17) | 3.1109(19) | 171(2) |
N2—H2N···O1 | 0.869(16) | 1.895(17) | 2.762(2) | 175(2) |
N3—H3N···O2 i | 0.891(16) | 1.895(17) | 2.774(3) | 168(2) |
N4—H4N···Cl3 | 0.871(16) | 2.267(17) | 3.138(2) | 178(2) |
O1—H1OA···Cl2 | 0.836(17) | 2.182(19) | 3.0014(18) | 167(3) |
O1—H1OB···Cl3 ii | 0.828(18) | 2.304(19) | 3.1217(18) | 169(3) |
O2—H2OA···O1 | 0.854(18) | 1.902(19) | 2.754(2) | 176(3) |
O2—H2OB···Cl3 iii | 0.851(18) | 2.35(2) | 3.1561(19) | 158(3) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kozanecka-Okupnik, W.; Wurst, K.; Neuner, S.; Nerdinger, S.; Gelbrich, T. 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate. Molbank 2023, 2023, M1673. https://doi.org/10.3390/M1673
Kozanecka-Okupnik W, Wurst K, Neuner S, Nerdinger S, Gelbrich T. 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate. Molbank. 2023; 2023(2):M1673. https://doi.org/10.3390/M1673
Chicago/Turabian StyleKozanecka-Okupnik, Weronika, Klaus Wurst, Sandro Neuner, Sven Nerdinger, and Thomas Gelbrich. 2023. "5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate" Molbank 2023, no. 2: M1673. https://doi.org/10.3390/M1673
APA StyleKozanecka-Okupnik, W., Wurst, K., Neuner, S., Nerdinger, S., & Gelbrich, T. (2023). 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate. Molbank, 2023(2), M1673. https://doi.org/10.3390/M1673